Drug Profile
MPC 1203
Latest Information Update: 09 Aug 2007
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals; Nonindustrial source
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Disseminated intravascular coagulation; Thrombosis
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Disseminated intravascular coagulation in USA (unspecified route)
- 09 Aug 2007 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 09 May 2001 Preclinical development for Disseminated intravascular coagulation in USA (Unknown route)